SCHEMBL2756476

SCHEMBL2756476

Cc1ccc2c(c1)Nc1ccc(C)cc1S2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 13/20 0.53
MAPT P10636 9/20 0.53
GAA P10253 7/20 0.53
MEN1 O00255 7/20 0.53
KMT2A Q03164 7/20 0.53
TDP1 Q9NUW8 3/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
EPHX2 P34913 1/20 0.49
MAPK1 P28482 3/20 0.48
SNCA P37840 3/20 0.48
NPSR1 Q6W5P4 1/20 0.48
ALOX15 P16050 4/20 0.47
HSD17B10 Q99714 2/20 0.47
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HTT P42858 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
BCHE P06276 2/20 0.46
ACHE P22303 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL225916 0.92 MAPT (0.59) NOX1MAPTGAAMEN1KMT2A
SCHEMBL29640485 0.92 MAPT (0.59) NOX1MAPTGAAMEN1KMT2A
SCHEMBL225814 0.92 NOX1 (0.47) NOX1MAPTGAAMEN1KMT2A
SCHEMBL239549 0.86 NOX1 (0.65) NOX1MAPTGAAMEN1KMT2A
SCHEMBL225829 0.86 NOX1 (0.65) NOX1MAPTGAAMEN1KMT2A
SCHEMBL2756739 0.85 NOX1 (0.50) NOX1MAPTGAAMEN1KMT2A
SCHEMBL9980103 0.85 NOX1 (0.54) NOX1MAPTGAAMEN1KMT2A
SCHEMBL10890272 0.81 NOX1 (0.61) NOX1MAPTGAAMEN1KMT2A
SCHEMBL24255127 0.81 MAPT (0.50) NOX1MAPTGAAMEN1KMT2A
SCHEMBL9391898 0.81 SNCA (0.55) NOX1MAPTGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2518111-B1 COMPOSITION AND LUMINESCENT ELEMENT OBTAINED USING SAME SUMITOMO CHEMICAL CO (JP) 2019-03-13 EP disclosed
US-9780308-B2 Composition and light emitting device using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-03 US disclosed
US-9780308-B2 Composition and light emitting device using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-03 US disclosed
US-20170029408-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2017-02-02 US disclosed
US-9511056-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2016-12-06 US disclosed
EP-3002281-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2016-04-06 EP disclosed
EP-2857394-A1 Antiviral compounds Gilead Pharmasset LLC (US) 2015-04-08 EP disclosed
US-8841278-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2014-09-23 US disclosed
US-20140249074-A1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC (US) 2014-09-04 US disclosed
US-8822430-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2014-09-02 US disclosed
US-20140039021-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-02-06 US disclosed
US-8575118-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2013-11-05 US disclosed
US-20130137877-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-05-30 US disclosed
US-20120306358-A1 COMPOSITION AND LIGHT EMITTING DEVICE USING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-06 US disclosed
US-20120306358-A1 COMPOSITION AND LIGHT EMITTING DEVICE USING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-06 US disclosed
EP-2518111-A1 COMPOSITION AND LUMINESCENT ELEMENT OBTAINED USING SAME Sumitomo Chemical Company, Limited (JP) 2012-10-31 EP disclosed
US-20120264711-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-10-18 US disclosed
US-20120157404-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-06-21 US disclosed
US-8088368-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170029408-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 NOX1 3704/4885MAPT 2923/4885GAA 151/4885
US-20130137877-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 NOX1 3704/4885MAPT 2923/4885GAA 151/4885
US-20120264711-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 NOX1 3704/4885MAPT 2923/4885GAA 151/4885
US-20120157404-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 NOX1 3704/4885MAPT 2923/4885GAA 151/4885
US-20140039021-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 NOX1 3704/4885MAPT 2923/4885GAA 151/4885
US-20100310512-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 NOX1 3704/4885MAPT 2923/4885GAA 151/4885
US-20140249074-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 NOX1 3704/4885MAPT 2923/4885GAA 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.